Tevogen Inc. Depreciation
Tevogen Inc. (TVGN) reported Depreciation of $60.54 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-14
- Tevogen Inc. depreciation for the quarter ending 2026-06-30 was $30.27K, a 66.90% decline year-over-year.
- Tevogen Inc. depreciation for the quarter ending 2026-03-31 was $30.27K, a 25.36% decline year-over-year.
- Tevogen Inc. depreciation for the quarter ending 2025-12-31 was $58.06K, a 43.18% increase year-over-year.
- Tevogen Inc. depreciation for the quarter ending 2025-09-30 was $518.00, a 98.72% decline year-over-year.
- Tevogen Inc. depreciation for fiscal 2025 was $190.57K, a 17.49% increase from fiscal 2024.
- Tevogen Inc. depreciation for fiscal 2024 was $162.21K, a 0.67% decline from fiscal 2023.
- Tevogen Inc. depreciation for fiscal 2023 was $163.30K.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $30.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $60.54K 10-Q · filed 2026-08-14 | $118.60K derived: sum of 3 quarters · filed 2026-08-14 | $119.11K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $30.27K 10-Q · filed 2026-05-15 | $88.33K derived: sum of 2 quarters · filed 2026-05-15 | $88.85K derived: sum of 3 quarters · filed 2026-05-15 | $180.29K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $58.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $58.58K derived: sum of 2 quarters · filed 2026-03-31 | $150.02K derived: sum of 3 quarters · filed 2026-08-14 | $190.57K 10-K · filed 2026-03-31 |
| 2025-09-30 | $518.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $91.96K derived: sum of 2 quarters · filed 2026-08-14 | $132.51K 10-Q · filed 2025-11-14 | $173.06K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $91.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $131.99K 10-Q · filed 2026-08-14 | $172.55K derived: sum of 3 quarters · filed 2026-08-14 | $213.10K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $40.55K 10-Q · filed 2026-05-15 | $81.11K derived: sum of 2 quarters · filed 2026-05-15 | $121.66K derived: sum of 3 quarters · filed 2026-05-15 | $162.21K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $40.55K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $81.11K derived: sum of 2 quarters · filed 2026-03-31 | $121.66K derived: sum of 3 quarters · filed 2026-03-31 | $162.21K 10-K · filed 2026-03-31 |
| 2024-09-30 | $40.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $81.11K derived: sum of 2 quarters · filed 2025-11-14 | $121.66K 10-Q · filed 2025-11-14 | $165.75K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $40.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $81.10K 10-Q · filed 2025-08-14 | $125.20K derived: sum of 3 quarters · filed 2025-08-14 | $164.93K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $40.55K 10-Q · filed 2025-05-14 | $84.65K derived: sum of 2 quarters · filed 2025-05-14 | $124.38K derived: sum of 3 quarters · filed 2025-05-14 | $164.12K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $44.09K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-02 | $83.83K derived: sum of 2 quarters · filed 2025-04-02 | $123.56K derived: sum of 3 quarters · filed 2025-04-02 | $163.30K 10-K · filed 2025-04-02 |
| 2023-09-30 | $39.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | $79.47K derived: sum of 2 quarters · filed 2024-11-19 | $119.21K 10-Q · filed 2024-11-19 | |
| 2023-06-30 | $39.74K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $79.47K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $39.73K 10-Q · filed 2024-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |